

Monica Ganzinelli

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/2646448/monica-ganzinelli-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

63
papers

1,740
citations

23
h-index

41
g-index

73
ext. papers

2,094
ext. citations

5.3
avg, IF

4.05
L-index

#	Paper	IF	Citations
63	Machine Learning Using Real-World and Translational Data to Improve Treatment Selection for NSCLC Patients Treated with Immunotherapy.. <i>Cancers</i> , 2022 , 14,	6.6	4
62	Predictive modeling of gene expression regulation. <i>BMC Bioinformatics</i> , 2021 , 22, 571	3.6	
61	Immunotherapy in advanced Non-Small Cell Lung Cancer patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkers. <i>Lung Cancer</i> , 2021 , 152, 165-173	5.9	11
60	LKB1 Down-Modulation by miR-17 Identifies Patients With NSCLC Having Worse Prognosis Eligible for Energy-Stress-Based Treatments. <i>Journal of Thoracic Oncology</i> , 2021 , 16, 1298-1311	8.9	5
59	miR-17 Epigenetic Modulation of LKB1 Expression in Tumor Cells Uncovers a New Group of Patients With Poor-Prognosis NSCLC. <i>Journal of Thoracic Oncology</i> , 2021 , 16, e68-e70	8.9	
58	Treatment patterns among patients with malignant pleural mesothelioma: An Italian, population-based nationwide study. <i>Thoracic Cancer</i> , 2020 , 11, 1661-1669	3.2	1
57	DiM: Prognostic Score for Second- or Further-line Immunotherapy in Advanced Non-Small-Cell Lung Cancer: An External Validation. <i>Clinical Lung Cancer</i> , 2020 , 21, e337-e348	4.9	4
56	mutations confer poor prognosis in malignant pleural mesothelioma. <i>Translational Lung Cancer Research</i> , 2020 , 9, 1940-1951	4.4	
55	SMO mutations confer poor prognosis in malignant pleural mesothelioma. <i>Translational Lung Cancer Research</i> , 2020 , 9, 1940-1951	4.4	0
54	Facing the First-line in Metastatic Non-small-cell Lung Cancer Immunotherapy and Chemotherapy. <i>European Oncology and Haematology</i> , 2020 , 16, 39	0.1	
53	Beyond Mutations in Non-Small Cell Lung Cancer: Defining LKB1less Phenotype to Optimize Patient Selection and Treatment. <i>Pharmaceuticals</i> , 2020 , 13,	5.2	3
52	Predicting the Role of DNA Polymerase β Alone or with Mutations in Advanced NSCLC Patients Receiving Platinum-Based Chemotherapy. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	1
51	mutations are not associated with the efficacy of first-line and second-line chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC): a post hoc analysis of the TAILOR trial. <i>ESMO Open</i> , 2020 , 5, e000748	6	1
50	Impact of ERCC1, XPF and DNA Polymerase β Expression on Platinum Response in Patient-Derived Ovarian Cancer Xenografts. <i>Cancers</i> , 2020 , 12,	6.6	3
49	Efficacy and safety of immunotherapy in elderly patients with non-small cell lung cancer. <i>Lung Cancer</i> , 2019 , 137, 38-42	5.9	29
48	Association between antibiotic-immunotherapy exposure ratio and outcome in metastatic non small cell lung cancer. <i>Lung Cancer</i> , 2019 , 132, 72-78	5.9	34
47	Modulation of peripheral blood immune cells by early use of steroids and its association with clinical outcomes in patients with metastatic non-small cell lung cancer treated with immune checkpoint inhibitors. <i>ESMO Open</i> , 2019 , 4, e000457	6	93

46	Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out. <i>Cancer Treatment Reviews</i> , 2019 , 75, 39-51	14.4	85
45	Characterization of patients with metastatic non-small-cell lung cancer obtaining long-term benefit from immunotherapy. <i>Future Oncology</i> , 2019 , 15, 2743-2757	3.6	5
44	Avelumab in gastric cancer. <i>Immunotherapy</i> , 2019 , 11, 759-768	3.8	8
43	The Prognostic Role of TNM Staging Compared With Tumor Volume and Number of Pleural Sites in Malignant Pleural Mesothelioma. <i>Clinical Lung Cancer</i> , 2019 , 20, e652-e660	4.9	2
42	Immune-checkpoints inhibitors in metastatic non small cell lung cancer with rare histology.. <i>Journal of Clinical Oncology</i> , 2019 , 37, 9106-9106	2.2	3
41	Impact of cholesterolemia and body mass index on outcome of metastatic non small cell lung cancer treated with immunotherapy.. <i>Journal of Clinical Oncology</i> , 2019 , 37, e20691-e20691	2.2	6
40	EPSILoN: A Prognostic Score for Immunotherapy in Advanced Non-Small-Cell Lung Cancer: A Validation Cohort. <i>Cancers</i> , 2019 , 11,	6.6	39
39	Antibody-Fc/FcR Interaction on Macrophages as a Mechanism for Hyperprogressive Disease in Non-small Cell Lung Cancer Subsequent to PD-1/PD-L1 Blockade. <i>Clinical Cancer Research</i> , 2019 , 25, 989-999	12.8	213
38	Exploiting Fasting-mimicking Diet and METformin to Improve the Efficacy of Platinum-pemetrexed Chemotherapy in Advanced LKB1-inactivated Lung Adenocarcinoma: The FAME Trial. <i>Clinical Lung Cancer</i> , 2019 , 20, e413-e417	4.9	15
37	RELEVANT Trial: Phase II Trial of Ramucirumab, Carboplatin, and Paclitaxel in Previously Untreated Thymic Carcinoma/B3 Thymoma With Area of Carcinoma. <i>Clinical Lung Cancer</i> , 2018 , 19, e811-e814	4.9	10
36	RANBP9 affects cancer cells response to genotoxic stress and its overexpression is associated with worse response to platinum in NSCLC patients. <i>Oncogene</i> , 2018 , 37, 6463-6476	9.2	8
35	Platinum sensitivity and DNA repair in a recently established panel of patient-derived ovarian carcinoma xenografts. <i>Oncotarget</i> , 2018 , 9, 24707-24717	3.3	12
34	Uncommon mutations in epidermal growth factor receptor and response to first and second generation tyrosine kinase inhibitors: A case series and literature review. <i>Lung Cancer</i> , 2018 , 115, 135-142	5.9	23
33	Low Baseline Serum Sodium Concentration Is Associated with Poor Clinical Outcomes in Metastatic Non-Small Cell Lung Cancer Patients Treated with Immunotherapy. <i>Targeted Oncology</i> , 2018 , 13, 795-800	5	14
32	Metformin Enhances Cisplatin-Induced Apoptosis and Prevents Resistance to Cisplatin in Co-mutated KRAS/LKB1 NSCLC. <i>Journal of Thoracic Oncology</i> , 2018 , 13, 1692-1704	8.9	49
31	Treatment in EGFR-mutated non-small cell lung cancer: how to block the receptor and overcome resistance mechanisms. <i>Tumori</i> , 2017 , 103, 325-337	1.7	6
30	Concomitant rearrangement and mutation in non-small cell lung cancer patients: a literature review of 100 cases. <i>Oncotarget</i> , 2017 , 8, 59889-59900	3.3	26
29	Small-Cell Lung Cancer: Clinical Management and Unmet Needs New Perspectives for an Old Problem. <i>Current Drug Targets</i> , 2017 , 18, 341-362	3	7

28	Co-existence of KRAS and LKB1 mutation as predictor of resistance to Erlotinib: Customized next-generation sequencing (NGS) of TAILOR trial.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e20631-e20631 ²		
27	Peptide receptor radionuclide therapy: focus on bronchial neuroendocrine tumors. <i>Tumor Biology</i> , 2016 , 37, 12991-13003	2.9	12
26	Systemic approach to malignant pleural mesothelioma: what news of chemotherapy, targeted agents and immunotherapy?. <i>Tumori</i> , 2016 , 102, 18-30	1.7	8
25	DNA repair gene polymorphisms in non-small-cell lung cancer patients treated with first-line platinum-containing chemotherapy. <i>Tumori</i> , 2016 , 102, 367-75	1.7	3
24	Treatment of lung large cell neuroendocrine carcinoma. <i>Tumor Biology</i> , 2016 , 37, 7047-57	2.9	34
23	Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of central nervous system metastases from non-small cell lung cancer: the present and the future. <i>Translational Lung Cancer Research</i> , 2016 , 5, 563-578	4.4	28
22	Body mass index and clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer. <i>Tumori</i> , 2016 , 102, e11-4	1.7	11
21	Characterization of MTAP Gene Expression in Breast Cancer Patients and Cell Lines. <i>PLoS ONE</i> , 2016 , 11, e0145647	3.7	14
20	The 5WTR variant of ERCC5 fails to influence outcomes in ovarian and lung cancer patients undergoing treatment with platinum-based drugs. <i>Scientific Reports</i> , 2016 , 6, 39217	4.9	0
19	Can the response to a platinum-based therapy be predicted by the DNA repair status in non-small cell lung cancer?. <i>Cancer Treatment Reviews</i> , 2016 , 48, 8-19	14.4	22
18	Diagnosis and management of typical and atypical lung carcinoids. <i>Critical Reviews in Oncology/Hematology</i> , 2016 , 100, 167-76	7	26
17	G48A, a New KRAS Mutation Found in Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2016 , 11, 1170-5	8.9	3
16	Value of KRAS as prognostic or predictive marker in NSCLC: results from the TAILOR trial. <i>Annals of Oncology</i> , 2015 , 26, 2079-84	10.3	35
15	Role of KRAS-LCS6 polymorphism in advanced NSCLC patients treated with erlotinib or docetaxel in second line treatment (TAILOR). <i>Scientific Reports</i> , 2015 , 5, 16331	4.9	9
14	KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapy. <i>Oncotarget</i> , 2015 , 6, 34014-22	3.3	48
13	Patient-derived ovarian tumor xenografts recapitulate human clinicopathology and genetic alterations. <i>Cancer Research</i> , 2014 , 74, 6980-90	10.1	89
12	Across the universe of K-RAS mutations in non-small-cell-lung cancer. <i>Current Pharmaceutical Design</i> , 2014 , 20, 3933-43	3.3	25
11	Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial. <i>Lancet Oncology</i> , 2013 , 14, 981-8	21.7	402

10	Tumor shrinkage and improved quality of life in a heavily pretreated metastatic breast cancer patient treated with eribulin. <i>Future Oncology</i> , 2013 , 9, 1703-9	3.6	2
9	Zebularine partially reverses GST methylation in prostate cancer cells and restores sensitivity to the DNA minor groove binder brostallicin. <i>Epigenetics</i> , 2013 , 8, 656-65	5.7	17
8	Randomised phase II trial (NCT00637975) evaluating activity and toxicity of two different escalating strategies for pregabalin and oxycodone combination therapy for neuropathic pain in cancer patients. <i>PLoS ONE</i> , 2013 , 8, e59981	3.7	20
7	Triple negative breast cancers have a reduced expression of DNA repair genes. <i>PLoS ONE</i> , 2013 , 8, e66243	3.7	27
6	Characterization of a new trabectedin-resistant myxoid liposarcoma cell line that shows collateral sensitivity to methylating agents. <i>International Journal of Cancer</i> , 2012 , 131, 59-69	7.5	22
5	Ovarian carcinoma tumor-initiating cells have a mesenchymal phenotype. <i>Cell Cycle</i> , 2012 , 11, 1966-76	4.7	38
4	TAILOR: A phase III trial comparing erlotinib with docetaxel as the second-line treatment of NSCLC patients with wild-type (wt) EGFR.. <i>Journal of Clinical Oncology</i> , 2012 , 30, LBA7501-LBA7501	2.2	26
3	Expression of DNA repair genes in ovarian cancer samples: biological and clinical considerations. <i>European Journal of Cancer</i> , 2011 , 47, 1086-94	7.5	28
2	Down-regulation of the nucleotide excision repair gene XPG as a new mechanism of drug resistance in human and murine cancer cells. <i>Molecular Cancer</i> , 2010 , 9, 259	42.1	27
1	Checkpoint kinase 1 down-regulation by an inducible small interfering RNA expression system sensitized in vivo tumors to treatment with 5-fluorouracil. <i>Clinical Cancer Research</i> , 2008 , 14, 5131-41	12.9	41